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Thrombocytosis and hyperfibrinogenemia
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in high-grade serous ovarian cancer
patients
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Abstract
Background: Over 20 % of ovarian cancer patients have preoperative thrombocytosis or hyperfibrinogenemia. We
aimed to demonstrate the clinical and prognostic significance of thrombocytosis and hyperfibrinogenemia in high-grade
serous ovarian cancer (HGSC).
Methods: We retrospectively investigated HGSC patients who underwent primary staging or debulking surgery between
April 2005 and June 2013 in our institution. None of these patients had received neoadjuvant chemotherapy. Data,
including age, performance status, FIGO stage, serum CA125, platelet count, fibrinogen level, and surgical residual disease,
were collected. Thrombocytosis was defined as a platelet count greater than 450 × 109/L, and hyperfibrinogenemia was
defined as a fibrinogen level higher than 4.00 g/L. Progression-free survival (PFS) and overall survival (OS) were analyzed
with the Kaplan-Meier method and log-rank tests for univariate analyses. For the multivariate analyses, Cox regression
analysis was used to evaluate the effects of the prognostic factors, which are expressed as hazard ratios (HRs).
Results: A total of 875 consecutive HGSC patients were identified. The median follow-up time was 29 (1–115) months.
The median (interquartile range, IQR) preoperative platelet count was 301 (235–383) × 109/L, and 121 (13.8 %) women
had thrombocytosis. The median (IQR) preoperative fibrinogen level was 3.85 (3.19–4.45) g/L, and 332 (45.9 %) of the
patients had hyperfibrinogenemia. Both preoperative thrombocytosis and hyperfibrinogenemia were associated with an
advanced FIGO stage (p = 0.008 and <0.001, respectively), an increased CA125 level (p = 0.004 and 0.001, respectively),
more extensive ascites (p < 0.001 and <0.001, respectively), more extensive residual disease (p < 0.001 and
<0.001, respectively) and chemosensitivity (p = 0.043 and <0.001, respectively). In the univariate analyses,
hyperfibrinogenemia was associated with reduced PFS (p < 0.001) and OS (p < 0.001). However, thrombocytosis
was not found to be a potential predictor of PFS (P = 0.098) or OS (p = 0.894). In the multivariate analyses,
hyperfibrinogenemia was an independent predictor of OS (p = 0.014) but not PFS (p = 0.062).
Conclusion: Preoperative thrombocytosis and hyperfibrinogenemia reflected tumor burden to some extent
and thus influenced treatment outcomes, and the fibrinogen level was found to be useful as a prognostic
predictor in the HGSC patients.
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Background
Ovarian cancer is the seventh most commonly diag-
nosed cancer and the eighth leading cause of cancer
death among females worldwide. There were 238,700 es-
timated new cases and 151,900 deaths in 2012 [1]. Can-
cer patients often present in a prothrombotic state.
Approximately 20 to 30 % of ovarian cancer patients
have preoperative thrombocytosis [2–4], and approxi-
mately 40 % of patients have preoperative hyperfibrino-
genemia [5, 6].
Serologic coagulation parameters, including platelet
count and fibrinogen level, have emerged as potential
preoperative predictors of clinical outcomes [3, 5, 7].
Several studies have shown that either thrombocytosis
or hyperfibrinogenemia is associated with an advanced
FIGO stage, more extensive residual disease, and poorer
prognoses in ovarian cancer patients [2–4]. However,
other studies have failed to draw similar conclusions [8, 9].
The data are still insufficient to define the clinical and
prognostic significance of platelet count and plasma
fibrinogen level in ovarian cancer.
Furthermore, previous studies have shown that epithe-
lial ovarian cancer is not a single disease but a group of
heterogeneous tumors based on distinctive morphologic
and molecular genetic features [10]. Previous research
has failed to individually evaluate the clinical and prog-
nostic values of platelet counts and fibrinogen levels ac-
cording to histologic type. Because the vast majority of
ovarian carcinomas are HGSC, the purpose of our study
was to investigate the clinical and prognostic significance
of the preoperative platelet count and fibrinogen level in




The clinical data were collected retrospectively from
women who underwent primary staging or debulking
surgery for HGSC between April 2005 and June 2013 at
Fudan University Shanghai Cancer Center. This study
was approved by the ethics committee of Fudan Univer-
sity Shanghai Cancer Center. All participants had pro-
vided written informed consent form. Patients were
excluded if they had received neoadjuvant therapy, had
been treated for recurrent disease, or were found to have
other histological diagnoses on pathological review.
Clinical and pathological data were obtained from the
medical records, cancer registries, and pathology reports.
Patient characteristics including age, FIGO stage, pre-
operative laboratory data (CA125 level, platelet count,
fibrinogen level), presence of ascites, surgical outcomes
(R0, R1 vs R2), date of surgery, date of progression or
recurrence, date of last follow-up, and the patient’s
disease status at last contact, were collected.
The histological diagnoses were based on the WHO
criteria, and all microscopic slides were reviewed by two
experienced gynecologic pathologists. Eight hundred
seventy-five consecutive patients were identified, and all
of the patients were followed up until December 31st,
2014.
Thrombocytosis was defined as platelet count greater
than 450 × 109/L. Hyperfibrinogenemia was defined as
fibrinogen level greater than 4.00 g/L. R0 was defined as
the absence of macroscopic residual disease (RD) after
surgery. R1 was defined as a maximal diameter of the
macroscopic residual disease after cytoreduction of <1 cm.
R2 was defined as a maximal diameter of residual disease
of ≥1 cm. The optimal surgery was defined as the combin-
ation of R0 and R1. Chemosensitivity was defined as a
time interval of 6 months or longer between the comple-
tion of platinum-based chemotherapy and the detection of
relapse. Chemoresistance was defined as disease progres-
sion during adjuvant chemotherapy or within the 6-
month interval between the completion of platinum-
based chemotherapy and the detection of relapse.
Progression-free survival (PFS) was defined as the time
interval from the date of primary surgery to the date of
disease progression or recurrence. Overall survival (OS)
was defined as the time interval from the date of the pri-
mary surgery to the date of death or the last follow-up.
Statistical analyses
SPSS statistical software (version 21.0, SPSS, IBM Inc,
New York, USA) was used for the statistical analyses. De-
scriptive statistics were used for the demographic data and
are summarized as the means with the standard deviations
(SD), the medians with the interquartile ranges (IQRs) or
ranges, or the frequencies with the percentages. The cat-
egorical data were compared with chi-square or Fisher’s
exact tests as appropriate. The PFS and OS were analyzed
with the Kaplan-Meier method, and log-rank tests were
used in the univariate analyses. For the multivariate ana-
lyses, Cox regression analysis was used to evaluate the
effects of the prognostic factors, which are expressed as
hazard ratios (HRs). P < 0.05 was considered statistically
significant, and all reported P values were 2-sided.
Results
Patient characteristics and their correlations with
thrombocytosis and hyperfibrinogenemia
The patient characteristics are shown in Table 1. Among
the 875 patients, 874 (99.9 %) had documented pre-
operative platelet counts and 724 (82.7 %) had docu-
mented fibrinogen levels. The median (IQR) platelet
count was 3.85 (3.19–4.45) × 109/L, and 121 (13.8 %)
women had preoperative thrombocytosis. The median
(IQR) fibrinogen level was 3.85 (3.19–4.45) g/L, and 332
(45.9 %) had preoperative hyperfibrinogenemia. Seventy-
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seven patients had coexisting thrombocytosis and hyperfi-
brinogenemia. Seventy-five (8.6 %) patients were early
stage (I-II) and 800 (91.4 %) were advanced stage (III-IV).
The correlations of the clinical characteristics with
preoperative thrombocytosis and hyperfibrinogenemia
are summarized in Tables 2 and 3, respectively. Both
preoperative thrombocytosis and hyperfibrinogenemia
were associated with an advanced FIGO stage (p = 0.008
and <0.001, respectively), an increased CA125 level
(p = 0.004 and 0.001, respectively) and more extensive
ascites (p < 0.001 and <0.001, respectively). There were
no significant correlations of age with thrombocytosis
or hyperfibrinogenemia (p = 0.493 and 0.117, respectively).
Treatment outcomes, survival analysis, and their correlations
with thrombocytosis and hyperfibrinogenemia
After primary surgery, 272 (31.1 %) of the patients were
debulked to R0, and 434 (49.6 %) were debulked to <1 cm
with macroscopic disease (R1). As the extent of residual
disease increased, the numbers of patients who presented
with thrombocytosis (R0, R1, and R2: 6.6 %, 15.4 %,
21.3 %, respectively, p < 0.001) and hyperfibrinogenemia
(30.3 %, 50.0 %, 61.5 %, respectively, p < 0.001) increased.
Pairwise comparisons revealed significant differences in
the prevalences of hyperfibrinogenemia between the R0,
R1 and R2 groups (R0 vs R1: p < 0.001, R0 vs R2: p < 0.001,
R1 vs R2: p = 0.026). Regarding the platelet counts, a
smaller proportion of the patients in the R0 group had
thrombocytosis compared with the R1 and R2 groups
(R0 vs R1: p = 0.001 and R0 vs R2: p < 0.001). How-
ever, the difference in the prevalence of thrombocyto-
sis between the R1 and R2 groups was not significant
(p =0.092).
Following primary surgery, 849 (97.0 %) patients had
received platinum-based adjuvant chemotherapy. Among
these patients, 568 (66.9 %) were chemosensitive
(Table 1). Greater proportions of the patients with che-
moresistant disease had documented thrombocytosis
(17.7 % vs 12.2 %, p = 0.043) and hyperfibrinogenemia
(59.5 % vs 39.2 %, p < 0.001) compared with the chemo-
sensitive patients. Next, we investigated the correlations
of chemosensitivity with thrombocytosis and hyperfibri-
nogenemia after stratification according to surgical out-
come. The prevalence of thrombocytosis was no longer
associated with chemosensitivity in the R0, R1 or R2
subgroups (pR0 = 0.744, pR1 = 0.660, and pR2 = 0.228). Re-
garding the fibrinogen levels, greater proportions of che-
mosensitive patients in the R0 and R1 groups had
hyperfibrinogenemia compared with the corresponding
chemoresistant patients (pR0 = 0.001 and pR1 = 0.004).
However, the difference in hyperfibrinogenemia between
the chemosensitive and chemoresistant patients was not
significant in the R2 group (p =1.000).
The median(range) follow-up time was 29 (1–115)
months. One hundred four (11.9 %) women experienced
disease progression during adjuvant chemotherapy, 499
(57.0 %) patients exhibited documented recurrence, and
345 (39.4 %) deaths were documented. The median
(95 % CI) PFS was 18 (16.8–19.2) months, and the 2-
year and 5-year PFSs were 38.1 and 19.4 %, respectively.
The median (95 % CI) OS was 58 (51.4–64.6) months,
and the 2-year and 5-year OSs were 79.3 and 48.8 %,
respectively.
Regarding PFS and OS, the known negative influ-
ences of advanced FIGO stage (p < 0.001 and <0.001,
respectively), the presence of residual disease (R0 vs
R1 + R2: p < 0.001 and <0.001, respectively), and che-
moresistance (p < 0.001 and <0.001, respectively) were
confirmed in the univariate analyses.
In the univariate analysis, preoperative hyperfibrinogen-
emia was associated with impaired PFS (15.0 (13.8–16.2)
vs 21.0 (17.8–24.2) months, p < 0.001, Fig. 1a). The women
with thrombocytosis tended to exhibit shorter PFSs than
Table 1 Patient Characteristics (n = 875)
Age at diagnosis, median (range), years 56 (30–90)
Follow-up time, median (range), months 29 (1–115)
Menopausal status Postmenopausal 602 68.8 %
Premenopausal 273 31.2 %
Vital status Died 345 39.4 %
Alive 448 51.2 %
Censored 82 9.4 %
Family history Yes 230 26.3 %
No 643 73.7 %
CA125 level <500 U/ml 193 22.6 %
≥500 U/ml 662 77.4 %
Ascites No 99 11.3 %
<500 ml 146 16.7 %
≥500 ml 629 72.0 %
FIGO Stage Early (I, II) 75 8.6 %
Advanced (III, IV) 800 91.4 %
Cytoreduction R0 272 31.1 %
R1 434 49.6 %
R2 169 19.3 %
Chemosensitivity Yes 568 66.9 %
No 237 27.9 %
NA 44 5.2 %
Platelet count (median, IQR)(×109/L) 301 (235–383)
Thrombocytosis Yes 121 13.8 %
No 753 86.2 %
Fibrinogen level (median, IQR)(g/L) 3.85 (3.19–4.45)
Hyperfibrinogenemia Yes 332 45.9 %
No 392 54.1 %
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those with normal platelet counts; however, this difference
was not significant (17.0 (14.1–19.9) vs 19.0 (17.5–20.5)
months, respectively, p=0.098; Fig. 1b). In the multivariate
analysis with adjustments for age, FIGO stage, cytoreduc-
tion outcome and chemosensitivity status, preoperative
hyperfibrinogenemia was not found to be independent
predictor of PFS (HR = 1.202, 95 % CI, 0.991–1.459,
p = 0.062; Table 4).
Hyperfibrinogenemia was associated with a shorter OS
(42 (35.2–48.8) vs 72 (58.5–85.5) months, p < 0.001) in
the univariate analysis, but thrombocytosis was not cor-
related with OS (54.0 (41.0–67.0) vs 58.0 (50.6–65.4)
months, p = 0.894; Fig. 2). In the multivariate analysis
with adjustments for age, FIGO stage, cytoreduction
outcome and chemosensitivity status, hyperfibrinogen-
emia was independently associated with a poorer OS
(HR = 1.523, 95 % CI, 1.179–1.967, p = 0.001; Table 5).
Discussion
In this large mono-institutional study, we demonstrated
that both thrombocytosis and hyperfibrinogenemia were
associated with clinicopathological characteristics and
treatment outcomes. Additionally, hyperfibrinogenemia
was correlated with poorer overall survival in the Chinese
patients with HGSC.
We found that both thrombocytosis and hyperfibrino-
genemia were associated with increased tumor stage, ele-
vated CA125 level, and more extensive ascites. These
finding are in accordance with the previous published
data from patients with epithelial ovarian cancer regard-
less of histologic type [2–5, 11], indicating that the plate-
let and fibrinogen levels seem to increase in parallel with
tumor progression and metastasis. Experimental studies
have proven that a hypercoagulable status can be
Table 2 Clinicopathologic parameters of the patients and thrombocytosis
Parameters Thrombocytosis P-value
Yes No
Age <56(427) 63(14.8 %) 364(85.2 %) 0.493
≥56(447) 58(13.0 %) 389(87.0 %)
FIGO Stage Early(74) 3(4.1 %) 71(95.9 %) 0.008
Advanced(800) 118(14.8 %) 682(85.2 %)
CA125 Level <500 U/ml(193) 15(7.8 %) 178(92.2 %) 0.004
≥500 U/ml(661) 103(15.6 %) 558(84.4 %)
Hyperfibrinogenemia Yes (332) 77(23.2 %) 255(76.8 %) <0.001
No (391) 15(3.8 %) 376(96.2 %)
Ascitesa No (99) 3(3.0 %) 96(97.0 %) <0.001
<500 ml(146) 5(3.4 %) 141(96.6 %)
≥500 ml(628) 113(18.0 %) 515(82.0 %)
Cytoreductionb R0(271) 18(6.6 %) 253(93.4 %) <0.001
R1(434) 67(15.4 %) 367(84.6 %)
R2(169) 36(21.3 %) 133(78.7 %)
Chemosensitivity Yes (567) 69(12.2 %) 498(87.8 %) 0.043
No (237) 42(17.7 %) 195(82.3 %)
aSubgroup analyses: PNo vs <500ml = 1.000, PNo vs >500ml < 0.001, P<500 ml vs <500ml < 0.001
bSubgroup analyses: PR0 vs R1 = 0.001, PR0 vs R2 < 0.001, PR1 vs R2 = 0.092




Age <56(362) 177(48.9 %) 185(51.1 %) 0.117
≥56(362) 155(42.8 %) 207(57.2 %)
FIGO Stage Early(62) 12(19.4 %) 50(80.6 %) <0.001
Advanced(662) 320(48.3 %) 342(51.7 %)
CA125 Level <500U/ml(157) 53(33.8 %) 104(66.2 %) 0.001
≥500U/ml(556) 272(48.9 %) 284(51.1 %)
Ascitesa No(85) 21(24.7 %) 64(75.3 %) <0.001
<500 ml(122) 22(18.0 %) 100(82.0 %)
≥500 ml(723) 289(56.0 %) 227(44.0 %)
Cytoreductionb R0(231) 70(30.3 %) 161(69.7 %) <0.001
R1(358) 179(50.0 %) 179(50.0 %)
R2(135) 83(61.5 %) 52(38.5 %)
Chemosensitivity Yes(474) 186(39.2 %) 288(60.8 %) <0.001
No(197) 118(59.5 %) 79(40.1 %)
aSubgroup analyses: PNo vs <500ml = 0.296, PNo vs >500ml < 0.001, P<500 ml
vs <500ml < 0.001
bSubgroup analyses: PR0 vs R1 < 0.001, PR0 vs R2 < 0.001, PR1 vs R2 = 0.026
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Table 4 Multivariable analysis of the factors associated with PFS
Characteristics HR 95 % CI P value
Age (as a continuous variable) 1.006 0.996 - 1.016 0.263
FIGO Stage Early Referent
Advanced 2.162 1.367 - 3.417 0.001
Cytoreduction R0 Referent
R1 1.266 1.001 - 1.603 0.049
R2 1.407 1.047 - 1.890 0.023
Chemosensitivity No Referent
Yes 0.083 0.065 - 0.107 <0.001
Hyperfibrinogenemia No Referent
Yes 1.202 0.991 - 1.459 0.062
Fig. 1 Kaplan-Meier curve of PFS stratified by hyperfibrinogenemia and
thrombocytosis. (a) Preoperative hyperfibrinogenemia was associated
with impaired PFS (p < 0.001). (b) The difference of PFS between
patients with and without thrombocytosis was not significant (p=0.098)
Fig. 2 Kaplan-Meier curve of OS stratified by hyperfibrinogenemia and
thrombocytosis. (a) Hyperfibrinogenemia was associated with a shorter
OS (p < 0.001). (b) Thrombocytosis was not correlated with OS (p=0.894)
Table 5 Multivariable analysis of the factors associated with OS
Characteristics HR 95 % CI P value
Age (as a continuous variable) 1.021 1.006 - 1.036 0.005
FIGO Stage Early Referent
Advanced 3.574 1.522 - 8.393 0.003
Cytoreduction R0 Referent
R1 1.518 1.060 - 2.175 0.023
R2 1.412 0.929 - 2.147 0.107
Chemosensitivity No Referent
Yes 0.193 0.146 - 0.255 <0.001
Hyperfibrinogenemia No Referent
Yes 1.413 1.074 - 1.859 0.014
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induced directly by the tumor cells themselves or indirectly
by the tumor-associated cytokines that are produced by
host macrophages or endothelial cells [2, 12, 13], and
interleukin-6 (IL-6) has been found to be a key regulator of
paraneoplastic thrombocytosis and hyperfibrinogenemia
[2, 12–15]. Consequently, we believe that coagulation
parameters could reflect tumor burden to some
extent. Additionally, IL-6-targeted therapy has been
found to be capable benefiting the treatment of ovar-
ian cancer [2, 16, 17].
Because they were correlated with increased disease bur-
den, platelet count and plasma fibrinogen level could be
considered to be predictors of surgical outcomes [2–6, 16].
Ma et al. [4] found that epithelial ovarian cancer patients
with thrombocytosis have a greater likelihood of suboptimal
cytoreduction (p = 0.035). Another multicenter study re-
ported that an elevated fibrinogen level is associated with
the presence of increased postoperative residual tumor
mass (p < 0.001), which might be due to the increased
operative complexity that results from increased tumor
burden. Our study confirmed that both thrombocytosis and
hyperfibrinogenemia were correlated with more extensive
post-surgical residual disease.
Additionally, we investigated the relationship between
hypercoagulability and chemosensitivity in HGSC patients
for the first time. We observed that more patients with
chemoresistant disease had documented thrombocytosis
and hyperfibrinogenemia compared with the chemosensi-
tive patients. Previous studies have demonstrated that
coagulation system components can promote tumor
growth, angiogenesis, and metastasis and thus interact
with cytotoxic drugs [12, 13, 18–21]. The response to
chemotherapy can be influenced by surgical residual dis-
ease, and we have proven that hypercoagulability was as-
sociated with more extensive residual disease. Therefore,
we investigated the correlation between hypercoagulability
and chemosensitivity following stratification by post-
surgical residual disease. We found that only hyperfibrino-
genemia was associated with chemosensitivity in the R0
and R1 groups and that thrombocytosis was no longer a
predictor of chemotherapy response.
Several previous studies have also shown that platelet
count and fibrinogen level are potential prognostic indi-
cators in ovarian cancer patients [2–6, 11]. Once acti-
vated, the coagulation system can directly or indirectly
promote disease progression and metastasis and thus
lead to poorer prognosis [13, 19–22]. Consequently, we
confirmed that hyperfibrinogenemia was an independent
predictor of poorer OS in HGSC patients; however, we
failed to demonstrate the prognostic significance of
thrombocytosis. Allensworth et al. [3] proved that
thrombocytosis is an independent predictor of PFS but
not OS; however, when these authors stratified the pa-
tients according to FIGO stage, they found that
thrombocytosis was no longer an independent predictor
of PFS in the advanced stage (HR = 1.31, 0.99–1.75). Per-
haps because the overwhelming majority (91.4 %) of our
patients were in the advanced stage, no differences ac-
cording to thrombocytosis were observed in our study.
The limitation of our study is that it was a retrospect-
ive study that depended on accurate documentation, and
thus the potential for recall bias existed. Additionally,
our center is one of the tertiary referral hospitals in
China, and over 90 % of patients in such hospitals have
advanced disease. Previous studies have shown that
other coagulation biomarkers, including D-dimer and
von Willebrand factor, can also reflect disease burden
and serve as prognostic predictors [7, 8]. However, these
parameters are not routinely examined in our daily
work.
Notwithstanding its limitation, this was a mono-
institutional retrospective study that included a large num-
ber of HGSC patients. This study involved a group of
homogenous patients with the same histology who were
treated within 9 years and underwent similar surgical pro-
cedures and consistent platinum-based chemotherapy regi-
mens. And this could increase the generalizability of our
study findings.
Conclusion
In conclusion, our study suggests that both preoperative
thrombocytosis and hyperfibrinogenemia reflect tumor
burden to some extent and thus are predictive factors of
treatment outcomes and that fibrinogen level could be
regarded as a prognostic predictor in HGSC patients.
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